WestGene, a biotech company dedicated to mRNA technology, has received FDA IND approval for its mRNA therapeutic cancer vaccine, WGc-043—marking the world’s first approval of an EB virus-related mRNA therapeutic cancer vaccine.
 
Founded by Dr. Yuquan Wei, Academician of the Chinese Academy of Sciences, and Dr. Xiangrong Song, WestGene has become a driving force in mRNA technology research and innovative drug development.
 
The FDA approval of WGc-043 offers new hope to patients with advanced EB virus-related cancers. EB virus is highly correlated with more than ten malignancies, including nasopharyngeal carcinoma (NPC), natural killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer, cervical cancer, and autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus. These are potential indications for WGc-043.
 
WGc-043 shows promising efficacy, low toxicity, broad applicability, efficient scalability, and cost effectiveness. It has already completed investigator-initiated trials (IIT) in NPC and NKTL, demonstrating superior safety and efficacy compared to other publicly available mRNA therapeutic cancer vaccines. Once successfully launched, WGc-043 will provide a new treatment option for patients with advanced EB virus-positive solid tumors and hematologic malignancies.